Reversible Erblindung durch ein invasives Prolaktinom

Schöfl-Siegert, Beate; Brabant, G.; Mühlen, A. von zur; Schöfl, Christof

doi:10.1055/s-2001-14418

Cited by 2 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another possible reason could be associated with radiotherapy; 11 cases (85%) in Group A and 7 cases (58%) in Group B received radiotherapy. Many authors [1,2,7,[8][9][10][11][12][13][14] confirm that visual symptoms of patients with giant prolactinomas can be relieved after several days to several weeks of bromocriptine treatment.…”

Section: Discussionmentioning

confidence: 90%

“…That is, pharmacotherapy (bromocriptine) was the only effective treatment for controlling the serum PRL level. [8][9][10][11][12][13][14]. Sieck [9] reported 24 cases of IGPs, with bromocriptine as the only treatment.…”

Section: Discussionmentioning

confidence: 97%

“…Bromocriptine, which is the most commonly used D-2-receptor agonist in our clinic, can normalize the serum prolactin level and decrease the volume of the tumor in 75∼92% of the patients with prolactinomas [5][6][7][8][9][10][11][12][13][14]. The primary mechanism is the selective activation of the D-2-receptor on the cell membrane of prolactin cells, thus inhibiting the expression of the PRLm- (4A, B).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Combined Treatment of Invasive Giant Prolactinomas

Gong

2005

Pituitary

View full text Add to dashboard Cite

The management of invasive giant prolactinomas (IGP) has been an area of some controversy. The relative roles of transsphenoidal surgery, craniotomy, radiation therapy and dopamine agonist based medical therapy are gradually becoming clarified. We report the results of management of 30 patients with IGP. Surgery was the initial therapy in 18 patients and was nearly always followed by adjunctive treatment with radiotherapy and/or bromocriptine. A second group of 12 patients had initial therapy with bromocriptine; 6 had subsequent radiotherapy and only 1 had transsphenoidal surgery. Outcomes with regard to relief of mass effect, visual improvement, pituitary function and complications of therapy were superior in the bromocriptine treated patients.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combined Treatment of Invasive Giant Prolactinomas

Gong

2005

Pituitary

View full text Add to dashboard Cite

show abstract

“…Although rare, reversible blindness can be observed after medical treatment too, especially in children and young people. [ 29 47 ]…”

Section: Discussionmentioning

confidence: 99%

Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population

Chentli

Azzoug

Daffeur

et al. 2015

Indian J Endocr Metab

View full text Add to dashboard Cite

Introduction:Prolactinomas are less frequent, but more invasive in males. Giant ones (≥4 cm) are extremely rare in literature. Their neurological, psychiatric and endocrine complications are life threatening. Our aim was to report the largest mono center series in order to analyze their frequency, their characteristics, and their complications.Subjects and Methods:All patients had clinical examination, hormonal, ophthalmological, and radiological assessment based on computed tomography scan and cerebral magnetic resonance imaging. Positive diagnosis was based on clinical symptoms, high prolactin ± immunohistochemy study. Mixed adenomas were excluded by hormonal exploration and immunohistochemy. For those who received medical treatment only, a reduction in tumor size was considered a supplementary positive point for the diagnosis.Results:Among 154 male prolactinomas seen between 1987 and 2013, we observed 44 giant tumors (28.5%). Median age = 36 years, and 38.3% were under 30. Median tumor height = 53.95 mm (40–130) and median prolactin = 15,715 ng/ml (n < 20). Solid and cystic aspect ± calcifications was observed in 25%. 42 had cavernous sinuses invasion. Other invasions were: Posterior= 65.9%, anterior= 63.6%, temporal= 15.9% and frontal = 9%. For endocrine complications: Hypogonadism = 98.4%, thyrotroph and corticotroph deficits were seen in respectively 34%, and 32%. Posterior pituitary insufficiency was observed in one case. For ophthalmological complications: Optic atrophy = 46%, Ptosis = 6.8%, diplopia/strabismus = 4.5%. Neurological complications were: Memory loss and/or unconsciousness = 18.2%, epilepsy = 15.9%, frontal syndrome = 9% and obstructive hydrocephalus = 6.8%.Conclusion:Giant prolactinomas account for 28% in our population. Severe neurological complications are frequent. But, obstructive hydrocephalus is rare, which argues for a slow progression.

show abstract

Reversible Erblindung durch ein invasives Prolaktinom

Cited by 2 publications

References 12 publications

Combined Treatment of Invasive Giant Prolactinomas

Combined Treatment of Invasive Giant Prolactinomas

Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population

Contact Info

Product

Resources

About